Aktis Oncology Inc
AKTSHealthcare|Biotechnology|USA
$27.88
-0.54 (-1.90%)
Tangible Book
$9.16
Financials
Financial Snapshot
Market Cap
$1.54B
Enterprise Value
$526.9M
Revenue (TTM)
$5.1M
Net Income (TTM)
$-33.5M
Cash & Equivalents
—
Net Cash/Share
$8.46
Free Cash Flow (TTM)
$-26.1M
Operating CF (TTM)
$-24.2M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$6.1M
Monthly Burn
$2.0M
Est. Runway
—
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $128.6M | $97.9M | $297.2M | $226.8M | $538.5M | |
| Operating Cash Flow | $-18.1M | $-30.0M | $14.8M | $-64.1M | $-39.5M | |
| Free Cash Flow | $-20.4M | $-33.8M | $11.9M | $-73.7M | $-45.5M | |
| Capital Expenditure | $-2.3M | $-3.8M | $-2.9M | $-9.6M | $-6.0M | |
| Financing Cash Flow | $120.0M | $0.00 | $183.3M | $-1.2M | $336.8M |
R&D Spending
R&D (TTM)
$36.5M
R&D Intensity
716.7%
R&D Growth YoY
-45.8%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.5M | $6.5M | $5.1M | |
| R&D Expense | $14.3M | $25.9M | $41.0M | $67.5M | $36.5M | |
| R&D % of Revenue | — | — | 2754.1% | 1038.2% | 716.7% | |
| SG&A | $5.1M | $7.7M | $11.3M | $12.6M | $7.9M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.5M | $6.5M | $5.1M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $1.5M | $6.5M | $5.1M | |
| R&D | $14.3M | $25.9M | $41.0M | $67.5M | $36.5M | |
| SG&A | $5.1M | $7.7M | $11.3M | $12.6M | $7.9M | |
| Operating Income | $-19.8M | $-34.8M | $-52.0M | $-74.7M | $-40.1M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-17.9M | $-28.6M | $-44.0M | $-63.7M | $-33.5M | |
| Net Income | $-17.9M | $-28.6M | $-44.0M | $-63.7M | $-33.5M | |
| EPS (Diluted) | -0.51 | -0.82 | -1.26 | -1.21 | -0.67 | |
| EBITDA | $-19.3M | $-33.6M | $-50.5M | $-72.4M | $-38.7M | |
| Shares Out. (M) | 34.87 | 34.87 | 34.87 | 52.52 | 48.63 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $128.6M | $29.5M | $37.2M | $37.8M | $371.6M | |
| Marketable Securities | $0.00 | $68.3M | $260.0M | $189.0M | $166.9M | |
| Total Current Assets | $132.5M | $100.2M | $300.9M | $230.3M | $543.9M | |
| Total Assets | $138.3M | $122.4M | $326.2M | $264.9M | $576.8M | |
| Total Current Liabilities | $5.3M | $6.2M | $18.8M | $31.2M | $27.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $157.6M | $168.7M | $414.0M | $411.0M | $70.7M | |
| Stockholders' Equity | $-19.2M | $-46.3M | $-87.8M | $-146.1M | $506.1M | |
| Retained Earnings | $-20.2M | $-48.9M | $-92.8M | $-156.6M | $-174.9M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $-18.1M | $-30.0M | $14.8M | $-64.1M | $-39.5M | |
| Capital Expenditure | $-2.3M | $-3.8M | $-2.9M | $-9.6M | $-6.0M | |
| Free Cash Flow | $-20.4M | $-33.8M | $11.9M | $-73.7M | $-45.5M | |
| Investing Cash Flow | $-2.3M | $-68.8M | $-190.4M | $66.0M | $-105.9M | |
| Financing Cash Flow | $120.0M | $0.00 | $183.3M | $-1.2M | $336.8M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $339.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $698.0K | $1.5M | $2.3M | $5.1M | $4.1M | |
| Net Change in Cash | $99.6M | $-98.8M | $7.6M | $625.0K | $191.4M |
Dilution Tracker
Shares outstanding grew 39.5% over 5 years — significant dilution
Shares Outstanding
49M
5-Year Share Growth
+39.5%
Stock Issuance (TTM)
$339.8M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 34.87 | 34.87 | 34.87 | 52.52 | 48.63 | |
| YoY Change % | — | 0.0% | 0.0% | 50.6% | -7.4% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $339.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $698.0K | $1.5M | $2.3M | $5.1M | $4.1M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | -3500.3% | -1149.5% | -786.4% | |
| Net Margin % | 0.0% | 0.0% | -2957.6% | -980.9% | -656.5% | |
| EBITDA Margin % | 0.0% | 0.0% | -3394.4% | -1113.7% | -759.9% | |
| FCF Margin % | 0.0% | 0.0% | 800.3% | -1134.5% | -512.0% | |
| ROE % | 0.0% | 0.0% | 0.0% | 0.0% | -44.1% | |
| ROA % | -13.0% | -22.0% | -19.6% | -21.6% | -9.0% | |
| R&D / Revenue | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S273.33
Historical165.49 / 227.69 / 311.37
Industry Med.9.49
P/B3.04
Historical1.84 / 2.22 / 3.47
Industry Med.2.93
EV/EBITDA-26.18
Historical-26.18 / -14.42 / -5.21
Industry Med.13.02
EV/Revenue198.99
Historical44.92 / 137.08 / 226.18
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$9.16
Net Current Assets
$8.560
Net-Net Working Capital
$8.46
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | N/A | N/A | At Loss | |
| PS Ratio | - | - | 0.00 | 0.00 | 273.33 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 3.04 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -26.18 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 198.99 |
Analyst Estimates & Quality
Altman Z-Score
13.46
Safe
Piotroski F-Score
N/A
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $17.83M | $14.86M | $2.00M |
| Net Income | $-82.53M | $-113.13M | $-155.06M |
| EPS | -1.61 | -2.04 | -2.75 |
| Book Value per Share | 2.02 | 3.41 | 0.00 |
| Operating Cash Flow per Share | -1.05 | -1.23 | 0.00 |
| Operating CF | $-51.06M | $-59.82M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor | $6.5M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $6.5M |